Treatment of Brain Metastases from Melanoma

Mayo Clinic Proceedings

Volumn 78, Issue 12, 2003, Pages 1529-1536

  McWilliams, Robert R ^a   Brown, Paul D ^a   Buckner, Jan C ^a   Link, Michael J ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DACARBAZINE; ETOPOSIDE; FOTEMUSTINE; INTERLEUKIN 2; NITROSOUREA DERIVATIVE; TEMOZOLOMIDE; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOTHERAPY; MEDICAL LITERATURE; MELANOMA; MOTONEURON; MOTOR DYSFUNCTION; NAUSEA; NEUTROPENIA; QUALITY OF LIFE; RADIATION DOSE; RADIOSURGERY; REVIEW; SENSORY DYSFUNCTION; SEPSIS; STEREOTAXIC SURGERY; SURGICAL TECHNIQUE; SYSTEMIC DISEASE; THROMBOCYTOPENIA; THROMBOSIS; TOXICITY; TREATMENT OUTCOME; TREMOR;

EID: 0345293093     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.12.1529     Document Type: Review

References (58)

1. de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983;43:3427-3433.
2. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma: a study of 216 autopsy cases. Am J Surg. 1978;135:807-810.
3. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42:660-668.
4. Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol. 1983;1:313-317.
5. Budman DR, Camacho E, Wittes RE. The current causes of death in patients with malignant melanoma. Eur J Cancer. 1978;14:327-330.
6. Einhorn LH, Burgess MA, Vallejos C, et al. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res. 1974;34:1995-2004.
7. National Cancer Institute. PDQ. Available at: http://cancer.gov/search/clinical_trials. Accessibility verified October 17, 2003.
8. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11-20.
9. Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93:9-18.
10. Konstadoulakis MM, Messaris E, Zografos G, Androulakis G, Karakousis C. Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases: is there a role for surgery? J Neurosurg Sci. 2000;44:211-218.
11. Zacest AC, Besser M, Stevens G, Thompson JF, McCarthy WH, Culjak G. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg. 2002;96:552-558.
12. Katz HR. The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system. Int J Radiat Oncol Biol Phys. 1981;7:897-906.
13. Bremer AM, West CR, Didolkar MS. An evaluation of the surgical management of melanoma of the brain. J Surg Oncol. 1978;10:211-219.
14. Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys. 1988;15:859-864.
15. Ziegler JC, Cooper JS. Brain metastases from malignant melanoma: conventional vs high-dose-per-fraction radiotherapy. Int J Radiat Oncol Biol Phys. 1986;12:1839-1842.
16. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494-500.
17. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29:711-717.
18. Wornom IL III, Smith JW, Soong SJ, McElvein R, Urist MM, Balch CM. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg. 1986;204:181-185.
19. Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res. 1971;31:830-833.
20. Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer. 1980;45:679-683.
21. Stridsklev IC, Hagen S, Klepp O. Radiation therapy for brain metastases from malignant melanoma. Acta Radiol Oncol. 1984;23:231-235.
22. Ellerhorst J, Strom E, Nardone E, McCutcheon I. Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases. Int J Radiat Oncol Biol Phys. 2001;49:93-97.
23. Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer. 2002;94:2265-2272.
24. Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma brain metastases: review of Roswell Park Memorial Institute experience. Cancer. 1994;53:2550-2552.
25. Gottlieb JA, Frei E III, Luce JK. An evaluation of the management of patients with cerebral metastases from malignant melanoma. Cancer. 1972;29:701-705.
26. Fell DA, Leavens ME, McBride CM. Surgical versus nonsurgical management of metastatic melanoma of the brain. Neurosurgery. 1980;7:238-242.
27. Cooper JS, Carella R. Radiotherapy of intracerebral metastatic malignant melanoma. Radiology. 1980;134:735-738.
28. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-751.
29. Hornsey S. The radiation response of human malignant melanoma cells in vitro and in vivo. Cancer Res. 1972;32:650-651.
30. Rofstad EK. Radiation biology of malignant melanoma. Acta Radiol Oncol. 1986;25:1-10.
31. Homsey S. The radiosensitivity of melanoma cells in culture. Br J Radiol. 1972;45:158.
32. Vlock DR, Kirkwood JM, Leutzinger C, Kapp DS, Fischer JJ. High-dose fraction radiation therapy for intracranial metastases of malignant melanoma: a comparison with low-dose fraction therapy. Cancer. 1982;49:2289-2294.
33. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485-1489.
34. Hagen NA, Cirrincione C, Thaler HT, DeAngelis LM. The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology. 1990;40:158-160.
35. Somaza S, Kondziolka D, Lunsford LD, Kirkwood JM, Flickinger JC. Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg. 1993;79:661-666.
36. Seung SK, Shu HK, McDermott MW, Sneed PK, Larson DA. Stereotactic radiosurgery for malignant melanoma to the brain. Surg Clin North Am. 1996;76:1399-1411.
37. Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL. Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery. 2002;51:656-665.
38. Gieger M, Wu JK, Ling MN, Wazer D, Tsai JS, Engler MJ. Response of intracranial melanoma metastases to stereotactic radiosurgery. Radiat Oncol Investig. 1997;5:72-80.
39. Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys. 1998;42:581-589.
40. Lavine SD, Petrovich Z, Cohen-Gadol AA, et al. Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery. 1999;44:59-64.
41. Mingione V, Oliveira M, Prasad D, Steiner M, Steiner L. Gamma surgery for melanoma metastases in the brain. J Neurosurg. 2002;96:544-551.
42. Pavlick AC. Chemotherapy approaches to melanoma. Dermatol Clin. 2002;20:709-712.
43. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer. 1999;85:1599-1605.
44. Beretta G, Bonadonna G, Cascinelli N, Morabito A, Veronesi U. Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study. Cancer Treat Rep. 1976;60:33-40.
45. Madajewicz S, West CR, Park HC, et al. Phase II study - intraarterial BCNU therapy for metastatic brain tumors. Cancer. 1981;47:653-657.
46. Boaziz C, Breau JL, Morere JF, Israel L. Brain metastases of malignant melanomas [in French]. Bull Cancer. 1991;78:347-353.
47. Kleeberg UR, Engel E, Israels P, et al. Palliative therapy of melanoma patients with fotemustine: inverse relationship between tumour load and treatment effectiveness: a multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res. 1995;5:195-200.
48. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990;66:1873-1878.
49. Margolin K, Atkins B, Thompson A, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002;128:214-218.
50. Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide [letter]. N Engl J Med. 2001;345:621-622.
51. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [published correction appears in J Clin Oncol. 2000;18:2351]. J Clin Oncol. 2000;18:158-166.
52. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [published correction appears in J Clin Oncol. 2000;18:2351]. J Clin Oncol. 2000;18:158-166.
53. Hwu WJ, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol. 2001;2:634-635.
54. Hwu W-J, Krown SE, Lis E, et al. Phase II study of temozolomide (TMZ) plus thalidomide in patients with brain metastasis from malignant melanoma [abstract]. Program Proc Am Soc Clin Oncol. 2003;22:720. Abstract 2894.
55. Mornex F, Thomas L, Mohr P, et al. Randomized phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma [in French]. Cancer Radiother. 2003;7:1-8.
56. Dardoufas C, Miliadou A, Skarleas C, et al. Concomitant temozolomide (TMZ) and radiotherapy (RT) followed by adjuvant treatment with temozolomide in patients with brain metastases from solid tumours [abstract]. Program Proc Am Soc Clin Oncol. 2001;20:75b. Abstract 2048.
57. Guirguis LM, Yang JC, White DE, et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother. 2002;25:82-87.
58. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 1994;12:627-642.